Zhao Hui-Jun, Ren Lin-Lin, Wang Zhen-Hua, Sun Tian-Tian, Yu Ya-Nan, Wang Ying-Chao, Yan Ting-Ting, Zou Weiping, He Jie, Zhang Yaou, Hong Jie, Fang Jing-Yuan
1. State Key Laboratory for Oncogenes and Related Genes Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Diseases, 145 Middle Shandong Road, Shanghai 200001, China.
2. Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Theranostics. 2014 Sep 19;4(12):1193-208. doi: 10.7150/thno.8712. eCollection 2014.
Recent studies have increasingly linked microRNAs to colorectal cancer (CRC). MiR-194 has been reported deregulated in different tumor types, whereas the function of miR-194 in CRC largely remains unexplored. Here we investigated the biological effects, mechanisms and clinical significance of miR-194. Functional assay revealed that overexpression of miR-194 inhibited CRC cell viability and invasion in vitro and suppressed CRC xenograft tumor growth in vivo. Conversely, block of miR-194 in APC(Min/+) mice promoted tumor growth. Furthermore, miR-194 reduced the expression of AKT2 both in vitro and in vivo. Clinically, the expression of miR-194 gradually decreased from 20 normal colorectal mucosa (N-N) cases through 40 colorectal adenomas (CRA) cases and then to 40 CRC cases, and was negatively correlated with AKT2 and pAKT2 expression. Furthermore, expression of miR-194 in stool samples was gradually decreased from 20 healthy cases, 20 CRA cases, then to 28 CRC cases. Low expression of miR-194 in CRC tissues was associated with large tumor size (P=0.006), lymph node metastasis (P=0.012) and shorter survival (HR =2.349, 95% CI = 1.242 to 4.442; P=0.009). In conclusion, our data indicated that miR-194 acted as a tumor suppressor in the colorectal carcinogenesis via targeting PDK1/AKT2/XIAP pathway, and could be a significant diagnostic and prognostic biomarker for CRC.
最近的研究越来越多地将微小RNA与结直肠癌(CRC)联系起来。据报道,miR-194在不同肿瘤类型中表达失调,而其在CRC中的功能在很大程度上仍未被探索。在此,我们研究了miR-194的生物学效应、机制及临床意义。功能分析显示,miR-194的过表达在体外抑制CRC细胞活力和侵袭,并在体内抑制CRC异种移植瘤生长。相反,在APC(Min/+)小鼠中阻断miR-194可促进肿瘤生长。此外,miR-194在体外和体内均降低了AKT2的表达。临床上,miR-194的表达从20例正常结直肠黏膜(N-N)病例到40例结直肠腺瘤(CRA)病例再到40例CRC病例逐渐降低,且与AKT2和pAKT2表达呈负相关。此外,粪便样本中miR-194的表达从20例健康病例、20例CRA病例到28例CRC病例也逐渐降低。CRC组织中miR-194低表达与肿瘤体积大(P=0.006)、淋巴结转移(P=0.012)及生存期短(HR =2.349,95%CI = 1.242至4.442;P=0.009)相关。总之,我们的数据表明,miR-194通过靶向PDK1/AKT2/XIAP途径在结直肠癌发生过程中起肿瘤抑制作用,并且可能是CRC的一个重要诊断和预后生物标志物。